Theranostic Innovative Strategies for Brain Diseases: New Insights on Neurovascular Unit-Associated Pathological Changes in Neurodegenerative Disorders and Aging
TL;DR
This review synthesizes emerging innovations in neurotheranostics—integrated diagnostic and therapeutic platforms—focusing on the neurovascular unit (NVU) as a central pathogenic driver and target, highlighting the potential of nanotechnology, engineered nanoparticles (NPs) and microRNAs (miRNAs) as precision tools for early detection and targeted CNS delivery.
Abstract
Central nervous system (CNS) disorders represent a significant healthcare challenge, with aging as the primary risk factor. Current clinical management remains predominantly symptomatic, as late-stage diagnosis and the blood–brain barrier (BBB) limit therapeutic efficacy. This review synthesizes emerging innovations in neurotheranostics—integrated diagnostic and therapeutic platforms—focusing on the neurovascular unit (NVU) as a central pathogenic driver and target. Evidence indicates that NVU and BBB dysfunction are early events in Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis, and Huntington’s diseases, often preceding classic neuropathological hallmarks. The review highlights the potential of nanotechnology, engineered nanoparticles (NPs) and microRNAs (miRNAs) as precision tools for early detection and targeted CNS delivery. Additionally, it discusses the transformative impact of artificial intelligence (AI) in facilitating personalized, predictive care. Transitioning from a generic “one-pill-for-one-disease” model to a patient-centered strategy targeting early NVU alterations is essential. Integrating AI, nanotechnology and NVU-focused strategies offers a promising path toward effective, personalized disease-modifying therapies.